IL232535B - 4-paragnane-21,17,11β-triol-20,3-dione derivatives for the treatment of eye conditions - Google Patents

4-paragnane-21,17,11β-triol-20,3-dione derivatives for the treatment of eye conditions

Info

Publication number
IL232535B
IL232535B IL232535A IL23253514A IL232535B IL 232535 B IL232535 B IL 232535B IL 232535 A IL232535 A IL 232535A IL 23253514 A IL23253514 A IL 23253514A IL 232535 B IL232535 B IL 232535B
Authority
IL
Israel
Prior art keywords
pregenen
triol
treatment
dione derivatives
ocular conditions
Prior art date
Application number
IL232535A
Other languages
English (en)
Hebrew (he)
Other versions
IL232535A0 (en
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47179019&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL232535(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of IL232535A0 publication Critical patent/IL232535A0/en
Publication of IL232535B publication Critical patent/IL232535B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL232535A 2011-11-11 2014-05-11 4-paragnane-21,17,11β-triol-20,3-dione derivatives for the treatment of eye conditions IL232535B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161558775P 2011-11-11 2011-11-11
PCT/US2012/064293 WO2013071009A1 (en) 2011-11-11 2012-11-09 4 - pregenen- 11ss - 17 - 21 -triol-3, 20 -dione derivatives for the treatment of ocular conditions

Publications (2)

Publication Number Publication Date
IL232535A0 IL232535A0 (en) 2014-06-30
IL232535B true IL232535B (en) 2019-09-26

Family

ID=47179019

Family Applications (2)

Application Number Title Priority Date Filing Date
IL232535A IL232535B (en) 2011-11-11 2014-05-11 4-paragnane-21,17,11β-triol-20,3-dione derivatives for the treatment of eye conditions
IL232534A IL232534A0 (en) 2011-11-11 2014-05-11 Pharmaceutical preparations and methods of using 4-paragnane-β21,17,11-triol-20,3-dione derivatives

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL232534A IL232534A0 (en) 2011-11-11 2014-05-11 Pharmaceutical preparations and methods of using 4-paragnane-β21,17,11-triol-20,3-dione derivatives

Country Status (24)

Country Link
US (7) US8865691B2 (enExample)
EP (2) EP2776040B1 (enExample)
JP (2) JP6158201B2 (enExample)
KR (2) KR102049615B1 (enExample)
CN (2) CN104185472B (enExample)
AR (1) AR088846A1 (enExample)
AU (3) AU2012335590B2 (enExample)
BR (2) BR112014011333B1 (enExample)
CA (3) CA2855290C (enExample)
CL (2) CL2014001243A1 (enExample)
CO (2) CO6970598A2 (enExample)
ES (1) ES2806603T3 (enExample)
HK (1) HK1200366A1 (enExample)
IL (2) IL232535B (enExample)
IN (2) IN2014CN03903A (enExample)
MX (3) MX365859B (enExample)
MY (2) MY172227A (enExample)
PH (2) PH12014501079B1 (enExample)
RU (2) RU2683775C2 (enExample)
SG (3) SG11201402225RA (enExample)
TW (1) TWI584809B (enExample)
UA (2) UA116622C2 (enExample)
WO (2) WO2013071010A1 (enExample)
ZA (2) ZA201403431B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
UA116622C2 (uk) 2011-11-11 2018-04-25 Аллерган, Інк. Похідні 4-прегенен-11ss-17-21-тріол-3,20-діону для лікування хвороб очей
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
ES2750523T3 (es) 2012-12-18 2020-03-26 Almirall Sa Derivados de ciclohexil y quinuclidinil carbamato que tienen actividades de agonista beta2 adrenérgicos y antagonistas muscarínicos M3
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
CN105814071A (zh) * 2013-12-13 2016-07-27 阿勒根公司 类固醇样化合物的多晶型物及其制备和使用方法
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
KR20170120161A (ko) * 2015-03-05 2017-10-30 알러간, 인코포레이티드 안과용 약물 전달을 위한 자가-유화 약물 전달 시스템(sedds)
WO2018053321A1 (en) * 2016-09-16 2018-03-22 Kala Pharmaceuticals, Inc. Particles, compositions, and methods for ophthalmic and/or other applications
WO2019055028A1 (en) * 2017-09-15 2019-03-21 Kala Pharmaceuticals, Inc. PARTICLES, COMPOSITIONS AND METHODS FOR OPHTHALMIC APPLICATIONS AND / OR OTHER APPLICATIONS
CN116023425B (zh) * 2023-03-28 2023-06-20 南京师范大学 曲安西龙衍生物及其医药用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6605514A (enExample) * 1966-04-25 1967-10-26
IT1056711B (it) * 1967-04-01 1982-02-20 Vismara F Spa Derivati dell idrocortisone
US3484436A (en) 1967-09-07 1969-12-16 Syntex Corp Bicyclo(2.2.2)octane - 1 - -carboxylate esters of delta**4 - pregnene corticoid steroids
GB1227992A (enExample) * 1968-01-23 1971-04-15 Koninklijke Gist Spiritus
US3693032A (en) 1971-04-23 1972-09-19 Ibm Antisaturation technique for ttl circuits
US3984544A (en) * 1975-02-28 1976-10-05 Schering Corporation Retinoic acid esters of steroids of the pregnane series, their use in the treatment of acne and pharmaceutical formulations useful therefor
JPS52136157A (en) * 1976-04-14 1977-11-14 Taisho Pharmaceut Co Ltd Preparation of steroid 17-esters
JPS60994B2 (ja) * 1976-07-26 1985-01-11 大正製薬株式会社 プレグナン系化合物の１７α―エステル類の製造法
DE2735110A1 (de) * 1977-08-04 1979-02-15 Hoechst Ag Corticoid-17-alkylcarbonate und verfahren zu ihrer herstellung
US4221787A (en) * 1978-03-28 1980-09-09 Interx Research Corporation Esteramide prodrugs of anti-inflammatory corticosteroids
US4221778A (en) * 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
DE4025342A1 (de) * 1990-08-10 1992-02-13 Hoechst Ag In 17-stellung substituierte corticoid-17-alkylcarbonate, verfahren zu deren herstellung und diese enthaltende arzneimittel
US6011023A (en) * 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
ATE241640T1 (de) * 1999-10-15 2003-06-15 Leo Pharm Prod Ltd Fusidinsäure-derivate
US6395721B1 (en) 2000-01-05 2002-05-28 Leonard Bloom Low potency unpreserved sterile topical corticosteroid compositions for dermatitis
NZ538932A (en) * 2002-08-29 2007-04-27 Boehringer Ingelheim Pharma 3-(sulfonamidoethyl)-indole derivatives for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative disease
JP2005008596A (ja) * 2003-06-20 2005-01-13 Kobayashi Pharmaceut Co Ltd 眼科用組成物
DK1755616T3 (da) * 2004-04-08 2013-11-25 Eye Co Pty Ltd Behandling af ekssudativ retinopati med mineralkortikoider
AU2005271700B2 (en) * 2004-07-12 2010-11-11 Allergan, Inc. Opthalmic compositions and methods for treating ophthalmic conditions
US7687484B2 (en) * 2006-05-25 2010-03-30 Bodor Nicholas S Transporter enhanced corticosteroid activity
US7691811B2 (en) * 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
EP1864668B1 (en) 2006-06-01 2012-11-21 Novagali Pharma S.A. Use of prodrugs for ocular intravitreous administration
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
JP2009053880A (ja) 2007-08-27 2009-03-12 Sony Broadband Solution Corp 情報処理装置、ならびにｃｐｕユニット
CN101970452A (zh) * 2007-12-21 2011-02-09 先灵公司 C20-c21取代的糖皮质激素受体激动剂
MX2010013562A (es) * 2008-06-26 2011-02-15 Anterios Inc Aplicacion dermica.
UA116622C2 (uk) 2011-11-11 2018-04-25 Аллерган, Інк. Похідні 4-прегенен-11ss-17-21-тріол-3,20-діону для лікування хвороб очей

Also Published As

Publication number Publication date
US10188667B2 (en) 2019-01-29
JP2014533274A (ja) 2014-12-11
JP2014533275A (ja) 2014-12-11
RU2014123471A (ru) 2015-12-20
MX2019006877A (es) 2019-08-22
MX2014005678A (es) 2014-12-10
US9433631B2 (en) 2016-09-06
AU2012335589B2 (en) 2017-08-31
CN104203247A (zh) 2014-12-10
HK1200366A1 (en) 2015-08-07
US20150057258A1 (en) 2015-02-26
TWI584809B (zh) 2017-06-01
UA116622C2 (uk) 2018-04-25
NZ624920A (en) 2017-06-30
MY172227A (en) 2019-11-18
PH12014501078B1 (en) 2014-07-28
EP2776040B1 (en) 2020-04-22
JP6158201B2 (ja) 2017-07-05
AR088846A1 (es) 2014-07-10
US20190365786A1 (en) 2019-12-05
IL232534A0 (en) 2014-06-30
PH12014501078A1 (en) 2014-07-28
CA2855290A1 (en) 2013-05-16
MX363669B (es) 2019-03-29
RU2683775C2 (ru) 2019-04-02
ZA201403430B (en) 2016-05-25
CL2014001243A1 (es) 2014-11-28
AU2012335590B2 (en) 2017-10-19
KR20140095548A (ko) 2014-08-01
WO2013071009A1 (en) 2013-05-16
US20170182062A1 (en) 2017-06-29
CA2855290C (en) 2017-02-28
CA2855929C (en) 2018-03-27
US8865691B2 (en) 2014-10-21
AU2018200436B2 (en) 2019-10-24
CN104203247B (zh) 2017-06-06
EP2776040A1 (en) 2014-09-17
CA2991883C (en) 2020-03-10
CN104185472A (zh) 2014-12-03
CA2855929A1 (en) 2013-05-16
HK1200367A1 (en) 2015-08-07
WO2013071010A1 (en) 2013-05-16
US8906892B2 (en) 2014-12-09
UA111867C2 (uk) 2016-06-24
CL2014001244A1 (es) 2014-11-14
CN104185472B (zh) 2017-06-13
IN2014CN03903A (enExample) 2015-10-16
MY182222A (en) 2021-01-18
BR112014011333A2 (pt) 2017-05-02
KR102049615B1 (ko) 2019-11-28
AU2012335590A1 (en) 2014-05-29
EP2776041A1 (en) 2014-09-17
US20130123223A1 (en) 2013-05-16
JP6216719B2 (ja) 2017-10-18
IL232535A0 (en) 2014-06-30
US20150005519A1 (en) 2015-01-01
SG11201402247PA (en) 2014-06-27
SG10201603766PA (en) 2016-07-28
TW201325596A (zh) 2013-07-01
BR112014011333B1 (pt) 2020-04-28
KR20140095549A (ko) 2014-08-01
RU2014123472A (ru) 2015-12-20
MX2014005679A (es) 2014-12-10
US20130123226A1 (en) 2013-05-16
PH12014501079A1 (en) 2014-07-28
CO6970609A2 (es) 2014-06-13
AU2012335589A1 (en) 2014-05-29
CA2991883A1 (en) 2013-05-16
US10493082B2 (en) 2019-12-03
BR112014011341A2 (pt) 2017-05-02
IN2014CN03919A (enExample) 2015-09-04
AU2018200436A1 (en) 2018-02-08
NZ624919A (en) 2016-10-28
RU2688159C2 (ru) 2019-05-20
US9717743B2 (en) 2017-08-01
PH12014501079B1 (en) 2014-07-28
MX365859B (es) 2019-06-18
ES2806603T3 (es) 2021-02-18
US20180147217A1 (en) 2018-05-31
CO6970598A2 (es) 2014-06-13
SG11201402225RA (en) 2014-06-27
ZA201403431B (en) 2016-05-25

Similar Documents

Publication Publication Date Title
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
HUS1900040I1 (hu) Makrociklusos származékok proliferatív betegségek kezelésére
ZA201403430B (en) 4-pregenen- 11ss -17 - 21-triols-3, 20- dione derivatives for the treatment of ocular conditions
ZA201405820B (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
ZA201403795B (en) Formulations for the treatment of diabetes
IL230830A0 (en) Cellular preparations for the treatment of degenerative diseases of the retina
IL230635A (en) An outgrowth of 4,3,2,1-tetrahydroquinoline used to treat diabetes
EP2882387A4 (en) EYE CHAIN TOWER FOR TREATING THE CHAMBERING ANGLE DELIVERY
SG2014014724A (en) METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
AP2013007179A0 (en) Glycoside derivatives and their uses for the treatment of diabetes
IL230960A0 (en) A device for the treatment of eye disease
ZA201403736B (en) Process for the preparation of sterol derivatives
PL2538918T3 (pl) Cytocholina do leczenia jaskry
IL230959A0 (en) A device for the treatment of eye disease
ZA201306613B (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
PL395469A1 (pl) Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego
SI2694056T1 (sl) Terapevtsko zdravljenje
ZA201309732B (en) Process for the preparation of dexlansoprazole
PT2777699T (pt) Dietilamina-2,5-di-hidroxibenzenossulfonato para o tratamento de degeneração macular relacionada com a idade
HK1193343A (en) Methods for treating diseases of the retina
IL228973A (en) Oxymetazoline for the treatment of rectal disorders
HK1189818A (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
HK1188955A (en) Methods for treating diseases of the retina
GB201108301D0 (en) IVlg treatment for patients with Myeloma
HK1197236B (en) Compounds for the treatment of addiction

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed